These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 16401806)

  • 1. A call for fairness in formulary decisions.
    Levinson W; Laupacis A
    Arch Intern Med; 2006 Jan; 166(1):16-8. PubMed ID: 16401806
    [No Abstract]   [Full Text] [Related]  

  • 2. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The case for a value-based formulary: striving for total lowest net cost.
    Weart W; Bauman GR
    Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of pharmacoeconomic guidelines for formulary approval: the Australian experience.
    Langley PC
    Clin Ther; 1993; 15(6):1154-76; discussion 1120. PubMed ID: 8111812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic analysis in formulary decisions: an international perspective.
    Johnson JA; Bootman JL
    Am J Hosp Pharm; 1994 Oct; 51(20):2593-8. PubMed ID: 7847423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective.
    Kessler JM
    Am Heart J; 1999 May; 137(5):S111-4. PubMed ID: 10220610
    [No Abstract]   [Full Text] [Related]  

  • 7. Managed care guidelines for the economic evaluation of pharmaceuticals.
    Langley PC; Martin RE
    Am J Manag Care; 1997 Jul; 3(7):1013-21. PubMed ID: 10173366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The drug formulary decision-making process.
    Brehany J; Cohen P; Sax MJ
    Healthplan; 1999; 40(3):85-92. PubMed ID: 10538088
    [No Abstract]   [Full Text] [Related]  

  • 9. Application of pharmacoeconomics to formulary decision making in managed care organizations.
    Suh DC; Okpara IR; Agnese WB; Toscani M
    Am J Manag Care; 2002 Feb; 8(2):161-9. PubMed ID: 11858228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of research abstracts in formulary decision making by the Joint Oncology Drug Review of Canada.
    Weizman AV; Griesman J; Bell CM
    Appl Health Econ Health Policy; 2010; 8(6):387-91. PubMed ID: 21043540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The military health services system model for pharmacoeconomic decision making.
    Ries AJ; Potyk RP; Brier KL; Miller MR; Tornow JJ; Weber MP; Finder SF; Reeves CS
    Med Interface; 1995 May; 8(5):132-7. PubMed ID: 10142786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacy and Therapeutics committee. Cost-containment considerations.
    Hochla PK; Tuason VB
    Arch Intern Med; 1992 Sep; 152(9):1773-5. PubMed ID: 1520043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economics of lipid management.
    Mullins CD
    Manag Care; 2001 Nov; 10(11 Suppl):17-8; discussion 19-24. PubMed ID: 11761626
    [No Abstract]   [Full Text] [Related]  

  • 14. Applying decision analysis to pharmacy management and practice decisions.
    Barr JT; Schumacher GE
    Top Hosp Pharm Manage; 1994 Jan; 13(4):60-71. PubMed ID: 10130685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How expert opinion influences P&T decisions.
    Manag Care; 2010 May; 19(5):52. PubMed ID: 20524369
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug formulary decision-making in two regional health authorities in British Columbia, Canada.
    Armstrong K; Mitton C; Carleton B; Shoveller J
    Health Policy; 2008 Dec; 88(2-3):308-16. PubMed ID: 18508151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Operation, formulary decision-making activities of a P & T Committee in a managed care setting.
    Adams J; Richardson J
    Hosp Formul; 1991 Apr; 26(4):291-4, 300-1. PubMed ID: 10109798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to use structured decision making in developing therapeutic, cost-effective formulary systems.
    Crane VS
    Hosp Formul; 1993 Oct; 28(10):859-62, 865-7. PubMed ID: 10129135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rethinking formulary strategy: management and measurement considerations.
    Nugent ME
    Am J Manag Care; 1999 Sep; 5(9):1202-4. PubMed ID: 10621084
    [No Abstract]   [Full Text] [Related]  

  • 20. Do P&T committees have enough power? Plans and PBMs are divided about sharing drug prices with clinicians. Is it better to have an administrative committee determine the formulary?
    Cross M
    Manag Care; 2007 Apr; 16(4):39-42. PubMed ID: 17491288
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.